Permanent chemotherapy-induced alopecia: Case report and review of the literature

Journal of the American Academy of Dermatology

Volumn 63, Issue 2, 2010, Pages 333-336

  Tallon, Ben ^a   Blanchard, Elizabeth ^b   Goldberg, Lynne J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

area under the curve; AUC; BMT; bone marrow transplantation; chemotherapy induced alopecia; CIA; HDC; high dose chemotherapy

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MINOXIDIL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ALOPECIA; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; DEHYDRATION; DRUG WITHDRAWAL; FAMILY HISTORY; FATIGUE; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HAIR FOLLICLE; HAIR GROWTH; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INTRADUCTAL CARCINOMA; LYMPH NODE BIOPSY; MALE TYPE ALOPECIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARTIAL MASTECTOMY; PATHOGENESIS; PRIORITY JOURNAL; PUNCH BIOPSY; VAGINITIS; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CARCINOMA IN SITU; CHEMICALLY INDUCED DISORDER; PAGET NIPPLE DISEASE; PATHOLOGY; REVIEW;

AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS;

EID: 77955301312     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.063     Document Type: Review

References (19)

1. V.J. Dorr A practitioner's guide to cancer-related alopecia Semin Oncol 25 1998 562 570
2. M. Machado, J.S. Moreb, and S.A. Khan Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation Bone Marrow Transplant 40 2007 979 982 (Pubitemid 350048197)
3. A. Tosti, B.M. Piraccini, C. Vincenzi, and C. Misciali Permanent alopecia after busulfan chemotherapy Br J Dermatol 152 2005 1056 1058 (Pubitemid 40704954)
4. M.E. de Jonge, R.A. Mathôt, O. Dalesio, A.D. Huitema, S. Rodenhuis, and J.H. Beijnen Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy Bone Marrow Transplant 30 2002 593 597 (Pubitemid 35414809)
5. D. Tran, R.D. Sinclair, A.P. Schwarer, and C.W. Chow Permanent alopecia following chemotherapy and bone marrow transplantation Australas J Dermatol 41 2000 106 108 (Pubitemid 30304005)
6. P. Ljungman, M. Hassan, A.N. Békássy, O. Ringdén, and G. Oberg Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants Bone Marrow Transplant 15 1995 869 871
7. B.W. Baker, C.L. Wilson, A.L. Davis, R.L. Spearing, D.N. Hart, and D.C. Heaton et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair re-growth Bone Marrow Transplant 7 1991 43 47
8. M. Vowels, L.L. Chan, N. Giri, S. Russell, and R. Lam-Po-Tang Factors affecting hair regrowth after bone marrow transplantation Bone Marrow Transplant 12 1993 347 350 (Pubitemid 23295517)
9. C. Prevezas, B. Matard, L. Pinquier, and P. Reygagne Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer Br J Dermatol 160 2009 883 885
10. J.E. Cortes, and R. Pazdur Docetaxel. J Clin Oncol 13 1995 2643 2655
11. N. Thatcher, and M. Lind Carboplatin in small cell lung cancer Semin Oncol 17 1 Suppl. 2 1990 40 48 (Pubitemid 20060006)
12. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
13. J. Baselga Clinical trials of single-agent trastuzumab (Herceptin) Semin Oncol 27 5 Suppl. 9 2000 20 26
14. Y. Aoki, T. Sato, I. Tsuneki, M. Watanabe, H. Kase, and K. Fujita Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer Int J Gynecol Cancer 12 2002 704 709 (Pubitemid 35388037)
15. M. Hassan, P. Ljungman, and P. Bulme et al. Busulphan bioavailability Blood 84 1994 2144 2150
16. R. Sinclair Diffuse hair loss: Anagen effluvium R. Sinclair, C. Banfield, R. Dawber, Handbook of diseases of the hair and scalp 1999 Blackwell Science Oxford 70 74 (Pubitemid 29251560)
17. T.O. Bleiker, N. Nicolaou, J. Traulsen, and P.E. Hutchinson 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans Br J Dermatol 153 2005 103 112
18. I.B. Bayer-Garner, R.D. Sanderson, and B.R. Smoller Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicle Am J Dermatopathol 24 2002 484 489
19. E.M. Peters, M.G. Stieglitz, C. Liezman, R.W. Overall, M. Nakamura, and E. Hagen et al. P75 neurotrophin receptor-mediated signaling promotes human hair follicle regression (catagen) Am J Pathol 168 2006 221 234